Modern Prodrug Design for Targeted Oral Drug Delivery

被引:63
作者
Dahan, Arik [1 ]
Zimmermann, Ellen M. [2 ]
Ben-Shabat, Shimon [1 ]
机构
[1] Ben Gurion Univ Negev, Fac Hlth Sci, Sch Pharm, Dept Clin Pharmacol, IL-84105 Beer Sheva, Israel
[2] Univ Florida, Div Gastroenterol, Dept Med, Gainesville, FL 32608 USA
关键词
molecular biopharmaceutics; membrane transporters; passive/active intestinal permeability; prodrug activation; targeted prodrug approach; IN-VITRO EVALUATION; L-VALYL ESTER; AMINOMETHYL)-1-CYCLOHEXANE ACETIC-ACID; INTESTINAL LYMPHATIC TRANSPORT; ORGANIC CATION TRANSPORTERS; INFLAMMATORY-BOWEL-DISEASE; WILD-TYPE; ACTIVATING ENZYME; TESTOSTERONE UNDECANOATE; SUBSTRATE-SPECIFICITY;
D O I
10.3390/molecules191016489
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
The molecular information that became available over the past two decades significantly influenced the field of drug design and delivery at large, and the prodrug approach in particular. While the traditional prodrug approach was aimed at altering various physiochemical parameters, e. g., lipophilicity and charge state, the modern approach to prodrug design considers molecular/cellular factors, e. g., membrane influx/efflux transporters and cellular protein expression and distribution. This novel targeted-prodrug approach is aimed to exploit carrier-mediated transport for enhanced intestinal permeability, as well as specific enzymes to promote activation of the prodrug and liberation of the free parent drug. The purpose of this article is to provide a concise overview of this modern prodrug approach, with useful successful examples for its utilization. In the past the prodrug approach used to be viewed as a last option strategy, after all other possible solutions were exhausted; nowadays this is no longer the case, and in fact, the prodrug approach should be considered already in the very earliest development stages. Indeed, the prodrug approach becomes more and more popular and successful. A mechanistic prodrug design that aims to allow intestinal permeability by specific transporters, as well as activation by specific enzymes, may greatly improve the prodrug efficiency, and allow for novel oral treatment options.
引用
收藏
页码:16489 / 16505
页数:17
相关论文
共 125 条
[1]
IMPROVING INTESTINAL-ABSORPTION OF WATER-INSOLUBLE COMPOUNDS - A MEMBRANE METABOLISM STRATEGY [J].
AMIDON, GL ;
LEESMAN, GD ;
ELLIOTT, RL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1980, 69 (12) :1363-1368
[2]
A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[3]
H+/amino acid transporter 1 (PAT1) is the imino acid carrier:: An intestinal nutrient/drug transporter in human and rat [J].
Anderson, CMH ;
Grenade, DS ;
Boll, M ;
Foltz, M ;
Wake, KA ;
Kennedy, DJ ;
Munck, LK ;
Miyauchi, S ;
Taylor, PM ;
Campbell, FC ;
Munck, BG ;
Daniel, H ;
Ganapathy, V ;
Thwaites, DT .
GASTROENTEROLOGY, 2004, 127 (05) :1410-1422
[4]
STRUCTURAL SPECIFICITY OF MUCOSAL-CELL TRANSPORT AND METABOLISM OF PEPTIDE DRUGS - IMPLICATION FOR ORAL PEPTIDE DRUG DELIVERY [J].
BAI, JPF ;
AMIDON, GL .
PHARMACEUTICAL RESEARCH, 1992, 9 (08) :969-978
[5]
Apical sodium dependent bile acid transporter (ASBT, SLC10A2): A potential prodrug target [J].
Balakrishnan, Anand ;
Polli, James E. .
MOLECULAR PHARMACEUTICS, 2006, 3 (03) :223-230
[6]
Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir [J].
Balimane, PV ;
Tamai, I ;
Guo, AL ;
Nakanishi, T ;
Kitada, H ;
Leibach, FH ;
Tsuji, A ;
Sinko, PJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 250 (02) :246-251
[7]
Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist [J].
Beaumont, K ;
Webster, R ;
Gardner, I ;
Dack, K .
CURRENT DRUG METABOLISM, 2003, 4 (06) :461-485
[8]
Vitamin D3-based conjugates for topical treatment of psoriasis:: Synthesis, antiproliferative activity, and cutaneous penetration studies [J].
Ben-Shabat, S ;
Benisty, R ;
Wormser, U ;
Sintov, AC .
PHARMACEUTICAL RESEARCH, 2005, 22 (01) :50-57
[9]
Prodrug-based intracellular delivery of anticancer agents [J].
Bildstein, L. ;
Dubernet, C. ;
Couvreur, P. .
ADVANCED DRUG DELIVERY REVIEWS, 2011, 63 (1-2) :3-23
[10]
Pharmaceutical and pharmacological importance of peptide transporters [J].
Brandsch, Matthias ;
Knuetter, Ilka ;
Bosse-Doenecke, Eva .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2008, 60 (05) :543-585